M. Ellis

Abstract C160: New class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs).

Emily E. Reid, E. K. Maloney, J. Pinkas, 2013 .

Abstract B195: Lorvotuzumab mertansine displays favorable pharmacokinetics and tumor delivery in mouse models.

J. Pinkas, H. Erickson, M. Ellis, 2011 .

Abstract 2644: Antibody-drug conjugates (ADCs) with a novel DNA-alkylating agent, DGN462, are highly potent in vitro and in vivo against human cancer models

E. K. Maloney, R. Chari, N. Fishkin, 2014 .